



Diastereo- and enantioselective synthesis of *N,O*-nucleosides

Ugo Chiacchio,^{a,*} Antonino Corsaro,^a Daniela Iannazzo,^b Anna Piperno,^b Venerando Pistrà,^a Antonio Rescifina,^a Roberto Romeo,^b Giovanni Sindona^c and Giovanni Romeo^{b,*}

^aDipartimento di Scienze Chimiche, Università di Catania, Viale Andrea Doria 6, Catania 95125, Italy

^bDipartimento Farmaco-Chimico, Università di Messina, Viale SS. Annunziata, Messina 98168, Italy

^cDipartimento di Chimica, Università della Calabria, Arcavacata di Rende, Cosenza 87036, Italy

Received 17 June 2003; accepted 24 June 2003

Abstract—The diastereo- and enantioselective synthesis of α - and β -3'-hydroxymethyl-*N,O*-nucleosides is described, based on the 1,3-dipolar cycloaddition of a *N*-glycosyl nitron. Two approaches have been evaluated: the one-step procedure, which uses vinyl nucleobases, showed a better stereoselectivity towards β -nucleosides.

© 2003 Elsevier Ltd. All rights reserved.

1. Introduction

The improved knowledge of the HIV virus and its replication mechanism have suggested in recent years the synthesis of new molecules able to block the viral replication.¹ These compounds originate from chemical modifications of the nucleic acid fragments at the level of the sugar moiety and/or the heterocyclic base. In this context, the design of novel 'ribose' rings has resulted in the discovery of effective biological agents; promising results have been obtained from a new generation of nucleoside analogues where the ribose moiety has been replaced by either carbo- or heterocyclic rings.^{2–4}

The synthesis of isoxazolidinyl nucleosides **1**, unsubstituted on the nitrogen atom and in racemic form, has been recently reported:⁵ ADT **1** shows interesting antiviral and anti-AIDS activity (Fig. 1).




Figure 1. Isoxazolidinyl nucleosides.

The asymmetric version has also been investigated through the use of chiral dipoles.^{6,7} In this way, ADU, ADT, ADC, ADA and ADFU have been synthesized in enantiomerically pure form. (–)-ADFU shows promising biological properties: in particular it appears as a good inducer of apoptosis on lymphoid and monocytoid cells, acting as a strong potentiator of Fas-induced cell death.⁷

Herein we report a successful extension of the methodology towards the enantioselective synthesis of 3-hydroxymethyl derivatives of ADT, ADU, ADFU: the presence in the molecule of the hydroxymethyl group should promote the biological phosphorylation of the compounds and hence their biological activity.⁸

2. Results and discussion


N-Glycosylnitrones⁹ have been exploited as versatile building blocks in the preparation of the target modified nucleosides: the chiral auxiliary is easily introduced before the cycloaddition process and removed subsequently to give *N,O*-nucleosides unsubstituted on the nitrogen atom.

Thus, the reaction of (4*S*,5*R*)-5-[(1*R*)-2[[1-(*tert*-butyl)-1,1-diphenylsilyl]oxy]-1-hydroxyethyl]-2,2-dimethyl-1,3-dioxolane-4-carbaldehyde oxime **2**, with ethyl glyoxylate and vinyl acetate, in CHCl₃ at

* Corresponding authors. Tel.: +39-095-7385014; fax: +39-06-233208980; e-mail: uchiacchio@dipchi.unict.it

reflux at 60°C for 14 h gives, as previously reported,¹⁰ a mixture of two homochiral isoxazolidines **4** and **5**, epimeric at C₅, in a relative ratio *trans*/*cis* 1:1 (Scheme 1).

The two cycloadducts were independently converted in the (3*R*)-2-(5'-*O*-*tert*-butyldiphenylsilyl)-2',3'-*O*-isopropylidene-β-D-ribofuranosyl)-3-ethoxycarbonylisoxazolidin-5-one¹⁰ through hydrolysis with K₂CO₃, followed by oxidation with potassium permanganate. This result indicates that isoxazolidines **4** and **5** are



Scheme 1. Reagents and conditions: (i) Ethyl glyoxylate; (ii) vinyl acetate, 70°C; (iii) BSA, nucleobases, Me₃SiOTf in refluxed MeCN for 1 h, or SnCl₄, at 0°C for 2 h, and then overnight at rt; (iv) NaBH₄, dioxane:water 1:1, rt, 5 h; (v) 1.5% HCl in EtOH, rt, 3 h.

epimeric at C₅, while they possess the same stereochemistry at C₃ and C₁.

Thus, the cycloaddition reaction proceeds with a complete diastereofacial selectivity by involving, according to PM3 calculations,¹¹ the attack of dipolarophile on the *re*-face of nitrone in an *E*-*exo* and *E*-*endo* transition-state: in fact, an energy difference of 2.5 kcal/mol is observed in favor of the *re*-face attack with respect to the *si*-face one. This behaviour is also in accord with ab initio DFT calculations on C-methoxycarbonyl nitrone with vinyl acetate.¹² On these basis, the absolute configuration of the cycloadducts **4** and **5** can be tentatively assigned as (3*R*,5*R*) and (3*R*,5*S*) respectively.

The mixture of epimeric isoxazolidines **4** and **5** was then reacted with *N*,*O*-bis(trimethylsilyl)acetamide (BSA) and uracil **6a**, or thymine **6b**, in acetonitrile in the presence of TMSOTf or with 5-fluorouracil **6c** in CH₂Cl₂ at 0°C, in the presence of one equivalent of SnCl₄, to afford, with moderate stereoselectivity and good yields, the expected α- and β-nucleosides **7a–c** and **8a–c**, respectively (ratio 2.2:1), in enantiomerically pure form.

The structures of the obtained compounds were assessed on the basis of analytical and spectroscopic data (see Section 3). The ¹H NMR spectra of compounds **7a–c** showed the diagnostic resonances of H_{5'} as dd, in the range 6.23–6.24 ppm, while H_{3'} protons appear as dd, at 4.16–4.17 ppm; the methylene group at C_{4'} resonate as ddd at 2.40–2.41 and 2.99–2.99. For compounds **8a–c**, H_{5'} protons resonate as dd at 5.94–6.43, while H_{3'} appear as dd at 4.05–4.12 ppm. Noteworthy, in **8a–c** H_{5'} protons show a long-range coupling with H_{3'}, thus indicating a *cis* topological arrangement.


The stereochemical assignments have been performed on the basis of NOE and T-Roesy measurements. Irradiation of the H_{5'} signal in **8a–c** (*cis*) induces a positive NOE effect on the upfield resonance of methylene protons at C_{4'}; in turn, irradiation of this proton gives rise to enhancement of the H_{3'} resonance, thus indicating that these protons are in a *cis* arrangement. As confirmation, T-Roesy experiments reveal an intense NOE effect between H_{5'}, H_{4'b} and H_{3'}.

Conversely, nucleosides **7a–c** (*trans*) shows a NOE correlation between H_{5'} and the upfield resonance at C_{4'}, but only a negligible NOE effect between this last resonance and H_{3'}.

The reduction of the ester function was performed by treatment with NaBH₄ in dioxane/H₂O 1:1 to give 3'-hydroxymethyl derivatives **9a–c** and **10a–c**. Finally, the synthetic scheme was completed by removal of the sugar moiety, which was easily achieved by treatment with 1.5% aqueous HCl, to afford the target nucleosides **11** (α) and **12** (β), in enantiomerically pure form, with a satisfactory global yield starting from nitrone **3**. However, all the attempts to obtain uracil derivatives **11a** and **12a** failed.

A valuable improvement in the synthetic strategy has been exploited through the use of vinylated nucleobases, as dipolarophiles, to afford modified isoxazolidinyl nucleosides **7** and **8** in one step.

Thus, ribosyl oxyme **2** was reacted with ethyl glyoxylate and vinyl bases **13a–c** in CHCl_3 at 60°C for 12 h to afford nucleosides **7** and **8** in a 1:1.4 ratio (global yield 48%). In this case the reaction pathway appears to be different from the one presented in the above procedure, based on the Vorbrüggen nucleosidation; in fact, β -nucleosides **8a,c** are the major adducts. No attack of dipole to the double bond of nucleobases has been observed (Scheme 2).



Scheme 2. Reagents and conditions: (i) Ethyl glyoxylate, vinyl bases **13a–c**, 60°C , CHCl_3 , 12 h.

The cycloaddition reaction shows, besides a complete diastereofacial selectivity, a moderate *cis/trans* diastereoselectivity, which can be rationalized by assuming that the *E-endo* attack of the dipolarophile on the *re*-face of the nitrone is the preferred reaction pathway, because of secondary orbital interactions exerted by the pyrimidine ring of nucleobases.

In conclusion, the enantioselective synthesis of α - and β -3'-hydroxymethyl-*N,O*-nucleosides has been described. Two different approaches have been evaluated: the two-step procedure, based on the 1,3-dipolar cycloaddition of the chiral nitrone **3** with vinyl acetate, followed by Vorbrüggen nucleosidation, leads to better yields with respect to the one-step approach based on the cycloaddition reaction, performed with vinyl nucleobase. In this latter case, however, the procedure shows an improved stereoselectivity towards the formation of β adducts.

The designed methodologies appear versatile and extendable to the synthesis of all *N,O*-nucleosides containing different purine and pyrimidine bases. Tests on the biological activity of the synthesized compounds are in progress.

3. Experimental

Melting points were determined with a Kofler apparatus and are uncorrected. Elemental analyses were performed with a Perkin–Elmer elemental analyzer. IR spectra were recorded on a Perkin–Elmer Paragon 500 FT-IR Spectrometer using potassium bromide discs. NMR spectra were recorded on a Varian instrument at

200 or 500 MHz (^1H) and at 50 or 125 MHz (^{13}C) using deuteriochloroform or deuterated methanol as solvent; chemical shifts are given in ppm from TMS as internal standard. Thin-layer chromatographic separations were performed on Merck silica gel 60-F₂₅₄ precoated aluminium plates. Preparative separations were made by flash column chromatography using Merck silica gel 0.063–0.200 mm and 0.035–0.070 mm, respectively, with chloroform-methanol mixtures as eluent. HPLC purifications were made with a preparative column (Microsorb Dynamax 100Å, 21.4×250 mm). The purity of all homochiral compounds has been tested with a Nucleosil Chiral-2, 4×250 mm column with mixtures of *n*-hexane-2-propanol as eluent.

The identification of samples from different experiments was secured by mixed mps and superimposable IR spectra.

3.1. Starting materials

Ethyl glyoxylate, thymine, uracil, fluorouracil, and D-ribose were purchased from Aldrich Co. Isoxazolidines **4** and **5**,¹⁰ and vinyl bases **13**¹³ were prepared as already reported. All solvents were dried according to standard procedures.

3.2. Method A. General procedure for reactions between bases **6a,b** and isoxazolidines **4** and **5**

A suspension of bases **6a–c** (0.618 mmol) in dry acetonitrile (3 mL) was treated with *N,O*-bis(trimethylsilyl)acetamide (2.54 mmol) and refluxed for 15 min; to the clear solution obtained was added a solution of isoxazolidine **4** and **5** (0.517 mmol) in dry acetonitrile (3 mL) and then trimethylsilyltriflate (0.78 mmol) dropwise; the reaction mixture was refluxed for 1 h. After being cooled to 0°C , the solution was neutralized by careful addition of aqueous 5% sodium bicarbonate, and then it was concentrated in vacuo. To the crude was added dichloromethane (8 mL), and the organic phase was separated, washed with water (2×10 mL), dried over sodium sulfate, filtered, and evaporated to dryness. The residue was purified by radial chromatography (cyclohexane/ethyl acetate 3:2) and then by HPLC with a linear gradient of 2-propanol (6–10%, 0–10 min, flow 3.5 mL/min) in *n*-hexane.

3.2.1. 1-[(3*R*,5*R*)-2-(5-*O*-*tert*-Butyldiphenylsilyl)-2,3-*O*-isopropylidene- β -D-ribofuranosyl]-3-ethoxycarbonyl-1,2-isoxazolidin-5-yl]-1*H*-pyrimidine-2,4-dione **7a.** Yield 20%; HPLC: t_R 20.5 min. Oil; $[\alpha]_D^{25} = +15.3$ (c 2.01, CHCl_3). ^1H NMR (CDCl_3 , 500 MHz) δ : 1.06 (s, 9H), 1.19 (t, 3H, $J=7.5$ Hz), 1.34 (s, 3H), 1.52 (s, 3H), 2.40 (ddd, 1H, $J=6.5, 7.4, 14.0$ Hz, H_{4a}), 2.99 (ddd, 1H, $J=2.0, 7.0, 13.0$ Hz, H_{4b}), 3.74 (dd, 1H, $J=6.0, 11.0$ Hz, $\text{H}_{5'a}$), 3.76 (dd, 1H, $J=5.0, 11.5$ Hz, $\text{H}_{5'b}$), 4.09 (dq, 1H, $J=7.5, 15.5$ Hz), 4.10 (dq, 1H, $J=7.5, 15.5$ Hz), 4.16 (dd, 1H, $J=2.0, 8.0$ Hz, $\text{H}_{3'}$), 4.22 (ddd, 1H, $J=2.5, 5.0, 6$ Hz, $\text{H}_{4'}$), 4.65 (dd, 1H, $J=3.0$ e 6.5 Hz, $\text{H}_{2'}$), 4.71 (dd, 1H, $J=2.5, 6.5$ Hz, $\text{H}_{3'}$), 4.98 (d, 1H, $J=3.0$ Hz, $\text{H}_{1'}$), 5.66

(d, 1H, $J=8.0$ Hz, H_5), 6.24 (dd, 1H, $J=6.5$, 7.0 Hz, H_5), 7.37–7.43 (m, 6H), 7.60–7.43 (m, 5H), 8.93 (bs, 1H, NH). ^{13}C NMR (CDCl_3 , 125 MHz) δ : 13.9, 19.2, 25.3, 26.8, 27.1, 38.5, 61.5, 61.8, 63.7, 80.8, 82.8, 85.4, 98.9, 102.7, 113.6, 127.8, 129.9, 129.9, 132.8, 132.9, 135.5, 135.5, 139.6, 150.1, 163.1, 169.6. Anal. calcd for $\text{C}_{34}\text{H}_{43}\text{N}_3\text{O}_9\text{Si}$: C, 61.33; H, 6.51; N, 6.31%. Found: C, 61.31; H, 6.50; N, 6.32%.

3.2.2. 1-[(3*R*,5*S*)-2-(5-*O*-*tert*-Butyldiphenylsilyl)-2,3-*O*-isopropylidene- β -D-ribofuranosyl]-3-ethoxycarbonyl-1,2-isoxazolidin-5-yl]-1*H*-pyrimidine-2,4-dione 8a. Yield 44%; HPLC: t_R 18.4 min. Amorphous solid; $[\alpha]_D^{25} = -55.0$ (c 1.50, CHCl_3). ^1H NMR (CDCl_3 , 500 MHz) δ : 1.07 (s, 9H), 1.27 (t, 3H, $J=7.1$ Hz), 1.33 (s, 3H), 1.53 (s, 3H), 2.53 (ddd, 1H, $J=3.1$, 6.2, 13.9 Hz, H_{4a}), 2.87 (ddd, 1H, $J=7.7$, 9.7, 13.9 Hz, H_{4b}), 3.72 (dd, 1H, $J=6.0$, 13.0 Hz, $H_{5'a}$), 3.74 (dd, 1H, $J=6.0$, 13.0 Hz, $H_{5'b}$), 4.05 (dd, 1H, $J=6.2$, 9.7 Hz, H_3), 4.19 (dq, 2H, $J=7.1$, 10.5 Hz), 4.24 (dq, 1H, $J=3.5$ and 6.0 Hz, $H_{4'}$), 4.51 (dd, 1H, $J=3.5$, 6.2 Hz, $H_{3'}$), 4.77 (dd, 1H, $J=2.0$, 6.2 Hz, $H_{2'}$), 5.02 (dd, 1H, $J=1.1$, 2.0 Hz, $H_{1'}$), 5.71 (d, 1H, $J=8.1$ Hz, H_5), 5.94 (ddd, 1H, $J=1.1$, 3.1, 7.7 Hz, H_5), 7.37–7.45 (m, 6H), 7.69–7.70 (m, 4H), 7.80 (d, 1H, $J=8.1$ Hz, H_6), 8.45 (bs, 1H, NH). ^{13}C NMR (CDCl_3 , 125 MHz) δ : 14.1, 19.3, 25.4, 26.8, 27.2, 39.8, 60.4, 62.1, 64.4, 81.0, 82.7, 83.7, 86.6, 97.6, 102.2, 113.4, 127.7, 129.8, 129.9, 133.2, 135.6, 135.6, 140.4, 150.1, 162.9, 169.3. Anal. calcd for $\text{C}_{34}\text{H}_{43}\text{N}_3\text{O}_9\text{Si}$: C, 61.33; H, 6.51; N, 6.31%. Found: C, 61.35; H, 6.52; N, 6.33%.

3.2.3. 1-[(3*R*,5*R*)-2-(5-*O*-*tert*-Butyldiphenylsilyl)-2,3-*O*-isopropylidene- β -D-ribofuranosyl]-3-ethoxycarbonyl-1,2-isoxazolidin-5-yl]-5-methyl-1*H*-pyrimidine-2,4-(1*H*,3*H*)-dione 7b. Yield 58%; HPLC: t_R 13.5 min. White solid: mp 53–56°C from EtOAc; $[\alpha]_D^{25} = -36.2$ (c 1.08; CHCl_3). Anal. calcd for $\text{C}_{35}\text{H}_{45}\text{N}_3\text{O}_9\text{Si}$: C, 61.84; H, 6.67; N, 6.18%. Found: C, 61.81; H, 6.69; N, 6.14%. All spectroscopic data are identical to the reported ones.¹⁰

3.2.4. 1-[(3*R*,5*S*)-2-(5-*O*-*tert*-Butyldiphenylsilyl)-2,3-*O*-isopropylidene- β -D-ribofuranosyl]-3-ethoxycarbonyl-1,2-isoxazolidin-5-yl]-5-methyl-1*H*-pyrimidine-2,4-(1*H*,3*H*)-dione 8b. Yield 23%; HPLC: t_R 11.5 min. White solid: mp 51–55°C from EtOAc; $[\alpha]_D^{25} = +5.6$ (c 1.22; CHCl_3). Anal. calcd for $\text{C}_{35}\text{H}_{45}\text{N}_3\text{O}_9\text{Si}$: C, 61.84; H, 6.67; N, 6.18%. Found: C, 61.89; H, 6.65; N, 6.21%. All spectroscopic data are identical to the reported ones.¹⁰

3.3. Method B. General procedure for reactions between base 6c and isoxazolidines 4 and 5

To a stirred mixture of 5-fluorouracil 6c (1.5 mmol), and isoxazolidines 4 and 5 as epimeric mixtures in anhydrous CH_2Cl_2 was added *N,O*-bis(trimethylsilyl)acetamide (3.5 mmol). After 2 h of stirring at room temperature, the clear solution was cooled at 0°C and SnCl_4 was added. The mixture was warmed to room temperature, left to stir overnight and, finally, poured slowly into a mixture of cold saturated aqueous NaHCO_3 (5 mL) and CHCl_3 (10 mL). The resulting

emulsion was separated by filtration through Celite, the aqueous layer was extracted further with ethyl acetate (3×10 mL), and the combined organic layers were dried over Na_2SO_4 and evaporated under reduced pressure. The residue was purified by radial chromatography (cyclohexane/ethyl acetate 3:2) and then by HPLC with a linear gradient of 2-propanol (6–10%, 0–10 min, flow 3.5 mL/min) in *n*-hexane.

3.3.1. 5-Fluoro-1-[(3*R*,5*R*)-2-(5-*O*-*tert*-butyldiphenylsilyl)-2,3-*O*-isopropylidene- β -D-ribofuranosyl]-3-ethoxycarbonyl-1,2-isoxazolidin-5-yl]-1*H*-pyrimidine-2,4-dione 7c. Yield 38.2%; HPLC: t_R 16.8 min. White solid: mp 52–56°C from EtOAc; $[\alpha]_D^{25} = -31.2$ (c 0.08; CHCl_3). ^1H NMR (CDCl_3 , 500 MHz) δ : 1.00 (s, 9H), 1.13 (t, 3H, $J=7.1$ Hz), 1.28 (s, 3H), 1.46 (s, 3H), 2.30 (ddd, 1H, $J=6.7$, 7.0 and 13.6 Hz, H_{4a}), 2.90 (ddd, 1H, $J=1.8$, 7.1 and 13.6 Hz, H_{4b}), 3.70 (dd, 1H, $J=4.4$ and 11.3 Hz, $H_{5'a}$), 3.74 (dd, 1H, $J=5.4$ and 11.3 Hz, $H_{5'b}$), 4.05 (dq, 1H, $J=7.1$ and 14.8 Hz), 4.07 (dq, 1H, $J=7.1$ and 14.8 Hz), 4.11 (dd, 1H, $J=1.8$ and 7.0 Hz, H_3), 4.16 (ddd, 1H, $J=2.6$, 4.4 and 5.4 Hz, $H_{4'}$), 4.56 (dd, 1H, $J=3.3$ and 6.2 Hz, $H_{3'}$), 4.64 (dd, 1H, $J=2.6$ and 6.2 Hz, $H_{3'}$), 4.95 (d, 1H, $J=3.3$ Hz, $H_{1'}$), 6.19 (dd, 1H, $J=6.7$ and 7.1 Hz, H_5), 7.30–7.56 (m, 10H), 7.76 (d, 1H, $J=6.2$ Hz, H_6), 8.78 (bs, 1H, NH). ^{13}C NMR (CDCl_3 , 125 MHz) δ : 13.9, 19.2, 25.3, 26.9, 27.1, 38.4, 61.2, 61.9, 63.7, 80.5, 82.7, 85.2, 85.9, 99.1, 113.9, 124.0 (d, $J=33.8$ Hz), 127.8, 127.8, 129.9, 130.0, 132.8, 132.9, 135.5, 135.6, 140.6 (d, $J=232.7$ Hz), 155.9 (d, $J=27.5$ Hz), 169.5. Anal. calcd for $\text{C}_{34}\text{H}_{42}\text{FN}_3\text{O}_9\text{Si}$: C, 59.72; H, 6.19; N, 6.15%. Found: C, 59.91; H, 6.17; N, 6.14%.

3.3.2. 5-Fluoro-1-[(3*R*,5*S*)-2-(5-*O*-*tert*-butyldiphenylsilyl)-2,3-*O*-isopropylidene- β -D-ribofuranosyl]-3-ethoxycarbonyl-1,2-isoxazolidin-5-yl]-1*H*-pyrimidine-2,4-dione 8c. Yield 31.8%; HPLC: t_R 19.6 min. White solid: mp 51–55°C from EtOAc; $[\alpha]_D^{25} = -6.8$ (c 0.22; CHCl_3). ^1H NMR (CDCl_3 , 500 MHz) δ : 0.99 (s, 9H), 1.04 (t, 3H, $J=7.2$ Hz), 1.28 (s, 3H), 1.45 (s, 3H), 2.52 (ddd, 1H, $J=3.3$, 3.4, 14.0 Hz, H_{4a}), 2.82 (ddd, 1H, $J=7.7$, 9.9, 14.0 Hz, H_{4b}), 3.65 (dd, 1H, $J=4.0$, 11.2 Hz, $H_{5'a}$), 3.73 (dd, 1H, $J=6.4$, 11.2 Hz, $H_{5'b}$), 3.90 (dq, 1H, $J=7.2$, 10.8 Hz), 3.97 (dq, 1H, $J=7.2$, 10.8 Hz), 4.04 (ddd, 1H, $J=1.5$, 3.3, 9.9 Hz, H_3), 4.16 (ddd, 1H, $J=2.3$, 4.0, 6.4 Hz, $H_{4'}$), 4.61 (dd, 1H, $J=2.9$, 6.4 Hz, $H_{3'}$), 4.69 (d, 1H, $J=2.9$ Hz, $H_{1'}$), 4.70 (dd, 1H, $J=2.3$, 6.4 Hz, $H_{3'}$), 6.29 (dd, 1H, $J=1.5$, 3.4, 7.7 Hz, H_5), 7.30–7.63 (m, 10H), 7.91 (d, 1H, $J=6.2$ Hz, H_6), 9.30 (bs, 1H, NH). ^{13}C NMR (CDCl_3 , 125 MHz) δ : 13.9, 19.2, 25.2, 26.8, 38.1, 60.6, 62.0, 63.7, 81.0, 82.6, 85.2, 85.6, 100.3, 113.5, 124.9 (d, $J=35.1$ Hz), 127.9, 127.9, 130.0, 132.8, 132.9, 135.4, 135.5, 140.3 (d, $J=239.7$ Hz), 156.7 (d, $J=27.1$ Hz), 170.8. Anal. calcd for $\text{C}_{34}\text{H}_{42}\text{FN}_3\text{O}_9\text{Si}$: C, 59.72; H, 6.19; N, 6.15%. Found: C, 59.63; H, 6.21; N, 6.13%.

3.4. General procedure for reactions between vinyl-bases 13a–c and Vasella-type nitron 3

A suspension containing one of the vinyl bases 13a–c (1 equiv.), ribosyl hydroxylamine 2 (1 equiv.) and ethyl glyoxylate (1 equiv.) in chloroform (ca. 10 mL)

was heated in a sealed vessel at 60°C under stirring, until the ribosyl hydroxylamine was consumed (8 h); after this time, to the reaction mixture were added 0.5 equiv. of the ribosyl hydroxylamine and of formaldehyde and was left to react for additional 4 h. Removal of the solvent in vacuo affords a crude material which was purified by flash chromatography to give a mixture of homochiral isoxazolidines **7a–c** and **8a–c** (1.5:1, 40% global yield), which was purified by radial chromatography (cyclohexane/ethyl acetate 3:2) and then by HPLC with a linear gradient of 2-propanol (6–10%, 0–10 min, flow 3.5 mL/min) in *n*-hexane, shows physical and spectral data listed above.

3.5. General procedure for reduction of nucleosides **7**, **8**

To a stirred solution of **7a–c**, **8a–c** (1.0 mmol) in a 1:1 methanol/dioxane mixture (50 mL), was added at 0°C NaBH₄ (6 mmol) and the obtained mixture was stirred for 5 h. At the end of this time the solvent was removed and the residue was extracted with ethyl acetate (3×5 mL); the collected organic phases, dried over sodium sulphate, gave after evaporation of the solvent at reduced pressure a yellow oil, which was purified by flash chromatography (chloroform/methanol 85:15).

3.5.1. 1-[(3*R*,5*R*)-2-(5-*O*-*tert*-Butyldiphenylsilyl)-2,3-*O*-isopropylidene-β-D-ribofuranosyl]-3-hydroxymethyl-1,2-isoxazolidin-5-yl]-1*H*-pyrimidine-2,4-dione **9a.** Yield 86%; amorphous solid; $[\alpha]_D^{25} = -59.6$ (*c* 0.86; CHCl₃). ¹H NMR (CDCl₃, 500 MHz) δ : 1.01 (s, 9H), 1.24 (s, 3H), 1.43 (s, 3H), 2.21 (ddd, 1H, *J* = 5.6, 7.8, 13.4 Hz, H_{4'a}), 2.65 (ddd, 1H, *J* = 3.1, 7.6, 13.4 Hz, H_{4'b}), 3.56 (bs, 1H, OH), 3.59 (dd, 1H, *J* = 6.7, 12.4 Hz, H_{3'a}), 3.61 (dd, 1H, *J* = 3.4, 12.4 Hz, H_{3'b}), 3.64 (dddd, 1H, *J* = 3.1, 3.4, 6.7, 7.8 Hz, H_{3'}), 3.81 (dd, 1H, *J* = 4.5, 10.9 Hz, H_{5'a}), 3.84 (dd, 1H, *J* = 5.9, 10.9 Hz, H_{5'b}), 4.45 (ddd, 1H, *J* = 2.7, 4.5, 5.9 Hz, H_{4''}), 4.51 (dd, 1H, *J* = 2.7, 5.9 Hz, H_{3''}), 4.68 (dd, 1H, *J* = 3.1, 5.9 Hz, H_{2''}), 5.25 (d, 1H, *J* = 3.4 Hz, H_{1''}), 5.89 (d, 1H, *J* = 8.2 Hz, H₅), 6.33 (dd, 1H, *J* = 5.6, 7.6 Hz, H₅), 7.32–7.51 (m, 6H), 7.54 (d, 1H, *J* = 8.2 Hz, H₆), 7.63–7.66 (m, 4H), 9.04 (bs, 1H, NH). ¹³C NMR (CDCl₃, 125 MHz) δ : 12.6, 19.4, 25.0, 27.0, 27.2, 38.5, 62.7, 63.1, 64.1, 80.1, 83.4, 84.1, 85.5, 98.5, 103.5, 113.9, 127.8, 127.6, 130.0, 130.2, 132.7, 132.8, 135.5, 135.6, 135.7, 150.2, 164.0. Anal. calcd for C₃₂H₄₁N₃O₈Si: C, 61.62; H, 6.63; N, 6.74%. Found: C, 61.67; H, 6.61; N, 6.79%.

3.5.2. 1-[(3*R*,5*S*)-2-(5-*O*-*tert*-Butyldiphenylsilyl)-2,3-*O*-isopropylidene-β-D-ribofuranosyl]-3-hydroxymethyl-1,2-isoxazolidin-5-yl]-1*H*-pyrimidine-2,4-dione **10a.** Yield 75%; amorphous solid; $[\alpha]_D^{25} = +12.8$ (*c* 1.08; CHCl₃). ¹H NMR (CDCl₃, 500 MHz) δ : 0.99 (s, 9H), 1.21 (s, 3H), 1.41 (s, 3H), 2.11 (ddd, 1H, *J* = 5.6, 7.4, 13.5 Hz, H_{4'a}), 2.79 (ddd, 1H, *J* = 5.9, 8.1, 13.5 Hz, H_{4'b}), 3.44 (dddd, 1H, *J* = 6.3, 7.1, 8.1, 8.7 Hz, H_{3'}), 3.52 (dd, 1H, *J* = 8.7, 11.9 Hz, H_{3'b}), 3.57 (dd, 1H, *J* = 5.1, 11.1 Hz, H_{5'a}), 3.62 (bs, 1H, OH), 3.74 (dd, 1H, *J* = 6.4, 11.9 Hz, H_{3'a}), 3.80 (dd, 1H, *J* = 2.7, 11.1 Hz, H_{5'b}), 4.27 (ddd, 1H, *J* = 2.0, 2.7, 6.4 Hz, H_{4''}), 4.57 (dd, 1H, *J* = 2.0, 6.4 Hz,

H_{3''}), 4.70 (dd, 1H, *J* = 2.7, 6.4 Hz, H_{2''}), 4.95 (d, 1H, *J* = 2.7 Hz, H_{1''}), 5.86 (d, 1H, *J* = 8.0 Hz, H₅), 6.42 (dd, 1H, *J* = 5.6, 8.1 Hz, H₅), 7.33–7.41 (m, 6H), 7.50 (d, 1H, *J* = 8.0 Hz, H₆), 7.58–7.68 (m, 4H), 9.04 (bs, 1H, NH). ¹³C NMR (CDCl₃, 125 MHz) δ : 12.5, 19.3, 25.4, 26.6, 27.3, 38.2, 62.6, 63.9, 63.9, 80.7, 83.3, 84.4, 85.5, 98.1, 101.2, 113.6, 127.77, 127.84, 131.1, 131.8, 132.8, 133.0, 135.5, 135.6, 150.2, 163.4. Anal. calcd for C₃₂H₄₁N₃O₈Si: C, 61.62; H, 6.63; N, 6.74%. Found: C, 61.69; H, 6.62; N, 6.77%.

3.5.3. 1-[(3*R*,5*R*)-2-(5-*O*-*tert*-Butyldiphenylsilyl)-2,3-*O*-isopropylidene-β-D-ribofuranosyl]-3-hydroxymethyl-1,2-isoxazolidin-5-yl]-5-methyl-1*H*-pyrimidine-2,4-dione **9b.** Yield 93%; white foam; $[\alpha]_D^{25} = -42.9$ (*c* 0.35; CHCl₃). ¹H NMR (CDCl₃, 500 MHz) δ : 1.07 (s, 9H), 1.33 (s, 3H), 1.53 (s, 3H), 1.90 (d, 3H, *J* = 1.1 Hz), 2.41 (ddd, 1H, *J* = 5.8, 8.0, 13.6 Hz, H_{4'a}), 2.56 (ddd, 1H, *J* = 2.9, 7.7, 13.6 Hz, H_{4'b}), 3.24 (bs, 1H, OH), 3.57 (dd, 1H, *J* = 6.9, 12.1 Hz, H_{3'a}), 3.62 (dd, 1H, *J* = 3.3, 12.1 Hz, H_{3'b}), 3.68 (dddd, 1H, *J* = 2.9, 3.3, 6.9, 8.0 Hz, H_{3'}), 3.75 (dd, 1H, *J* = 4.7, 11.3 Hz, H_{5'a}), 3.81 (dd, 1H, *J* = 6.2, 11.3 Hz, H_{5'b}), 4.25 (ddd, 1H, *J* = 2.5, 4.7, 6.2 Hz, H_{4''}), 4.55 (dd, 1H, *J* = 2.5, 6.2 Hz, H_{3''}), 4.71 (dd, 1H, *J* = 2.9, 6.2 Hz, H_{2''}), 5.05 (d, 1H, *J* = 2.9 Hz, H_{1''}), 6.23 (dd, 1H, *J* = 5.8, 7.7 Hz, H₅), 7.36–7.46 (m, 6H), 7.54 (q, 1H, *J* = 1.1 Hz, H₆), 7.63–7.66 (m, 4H), 9.04 (bs, 1H, NH). ¹³C NMR (CDCl₃, 125 MHz) δ : 12.6, 19.2, 25.2, 26.8, 27.1, 38.1, 62.7, 63.0, 64.1, 80.5, 83.1, 83.9, 85.7, 98.5, 111.2, 113.5, 127.8, 127.8, 129.9, 130.0, 132.7, 132.9, 135.3, 135.5, 135.6, 150.4, 163.6. Anal. calcd for C₃₄H₄₅N₃O₇Si: C, 64.23; H, 7.13; N, 6.61%. Found: C, 64.47; H, 7.16; N, 6.59%.

3.5.4. 1-[(3*R*,5*S*)-2-(5-*O*-*tert*-Butyldiphenylsilyl)-2,3-*O*-isopropylidene-β-D-ribofuranosyl]-3-hydroxymethyl-1,2-isoxazolidin-5-yl]-5-methyl-1*H*-pyrimidine-2,4-dione **10b.** Yield 72%; white solid; mp 54–58°C; $[\alpha]_D^{25} = +5.1$ (*c* 0.31; CHCl₃). ¹H NMR (CDCl₃, 500 MHz) δ : 1.09 (s, 9H), 1.31 (s, 3H), 1.51 (s, 3H), 1.69 (bs, 1H, OH), 1.87 (d, 3H, *J* = 1.3 Hz), 2.19 (ddd, 1H, *J* = 5.3, 6.9, 13.7 Hz, H_{4'a}), 2.86 (ddd, 1H, *J* = 7.9, 8.8, 13.7 Hz, H_{4'b}), 3.49 (dddd, 1H, *J* = 6.2, 6.9, 8.1, 8.8 Hz, H_{3'}), 3.56 (dd, 1H, *J* = 5.3, 12.0 Hz, H_{5'a}), 3.79 (dd, 1H, *J* = 6.2, 11.3 Hz, H_{3'a}), 3.80 (dd, 1H, *J* = 8.1, 11.3 Hz, H_{3'b}), 3.81 (dd, 1H, *J* = 2.9, 12.0 Hz, H_{5'b}), 4.25 (ddd, 1H, *J* = 2.1, 2.9, 5.3 Hz, H_{4''}), 4.58 (dd, 1H, *J* = 2.1, 6.4 Hz, H_{3''}), 4.74 (dd, 1H, *J* = 2.9, 6.4 Hz, H_{2''}), 4.80 (d, 1H, *J* = 2.9 Hz, H_{1''}), 6.37 (dd, 1H, *J* = 5.3, 7.9 Hz, H₅), 7.39–7.46 (m, 6H), 7.60 (q, 1H, *J* = 1.3 Hz, H₆), 7.64–7.66 (m, 4H), 8.60 (bs, 1H, NH). ¹³C NMR (CDCl₃, 125 MHz) δ : 12.7, 19.2, 25.2, 26.8, 26.9, 29.6, 38.2, 62.9, 63.8, 64.5, 80.8, 82.7, 83.5, 85.9, 101.4, 111.1, 113.5, 127.9, 128.0, 130.0, 130.1, 132.6, 132.9, 135.5, 135.6, 150.3, 163.4. Anal. calcd for C₃₄H₄₅N₃O₇Si: C, 64.23; H, 7.13; N, 6.61%. Found: C, 64.37; H, 7.12; N, 6.58%.

3.5.5. 5-Fluoro-1-[(3*R*,5*R*)-2-(5-*O*-*tert*-butyldiphenylsilyl)-2,3-*O*-isopropylidene-β-D-ribofuranosyl]-3-hydroxymethyl-1,2-isoxazolidin-5-yl]pyrimidine-2,4(1*H*,3*H*)-dione **9c.** Yield 81%; white solid; mp 53–55°C from EtOAc; $[\alpha]_D^{25} = -40.8$ (*c* 0.30; CHCl₃). ¹H NMR (CDCl₃,

500 MHz) δ : 0.99 (s, 9H), 1.26 (s, 3H), 1.47 (s, 3H), 2.34 (ddd, 1H, $J=5.8, 7.9, 13.8$ Hz, H_{4a}), 2.53 (ddd, 1H, $J=2.5, 7.5, 13.8$ Hz, H_{4b}), 3.05 (bs, 1H, OH), 3.47 (dd, 1H, $J=6.8, 12.2$ Hz, H_{3a}), 3.57 (dd, 1H, $J=3.1, 12.2$ Hz, H_{3b}), 3.63 (dddd, 1H, $J=2.5, 3.1, 5.8, 6.8$ Hz, H_3), 3.70 (dd, 1H, $J=4.2, 11.1$ Hz, $H_{5'a}$), 3.74 (dd, 1H, $J=5.9, 11.1$ Hz, $H_{5'b}$), 4.18 (ddd, 1H, $J=2.7, 4.2, 5.9$ Hz, $H_{4'}$), 4.46 (dd, 1H, $J=2.7, 6.4$ Hz, $H_{3'}$), 4.58 (dd, 1H, $J=3.3, 6.4$ Hz, $H_{2'}$), 5.04 (d, 1H, $J=3.3$ Hz, $H_{1'}$), 6.14 (dd, 1H, $J=7.5, 7.9$ Hz, H_5), 7.32–7.61 (m, 10H), 7.80 (d, 1H, $J=6.2$ Hz, H_6), 8.76 (bs, 1H, NH). ^{13}C NMR (CDCl_3 , 125 MHz) δ : 25.3, 26.8, 27.2, 29.7, 38.5, 62.4, 62.8, 64.0, 80.1, 84.3, 85.4, 98.3, 113.8, 124.1 (d, $J=34.2$ Hz), 127.8, 127.9, 129.9, 130.0, 132.7, 133.0, 135.5, 135.6, 141.1 (d, $J=237.4$ Hz), 150.3, 157.0 (d, $J=27.9$ Hz). Anal. calcd for $\text{C}_{32}\text{H}_{40}\text{FN}_3\text{O}_8\text{Si}$: C, 59.89; H, 6.28; N, 6.55%. Found: C, 60.08; H, 6.25; N, 6.58%.

3.5.6. 5-Fluoro-1-[(3R,5S)-2-(5-O-*tert*-butyldiphenilsilyl)-2,3-O-isopropylidene- β -D-ribofuranosyl]-3-hydroxymethyl-1,2-isoxazolidin-5-yl]pyrimidine-2,4(1H,3H)-dione 10c. Yield 56%; amorphous solid; $[\alpha]_D^{25} = +15.0$ (c 0.27; CHCl_3). ^1H NMR (CDCl_3 , 500 MHz): δ 1.01 (s, 9H), 1.24 (s, 3H), 1.44 (s, 3H), 2.19 (ddd, 1H, $J=4.2, 7.3, 14.0$ Hz, H_{4a}), 2.85 (ddd, 1H, $J=7.7, 8.0, 14.0$ Hz, H_{4b}), 2.97 (bs, 1H, OH), 3.28 (dddd, 1H, $J=2.6, 4.6, 7.3, 8.0$ Hz, H_3), 3.49 (dd, 1H, $J=4.6, 12.0$ Hz, H_{3a}), 3.68 (dd, 1H, $J=4.9, 11.3$ Hz, $H_{5'a}$), 3.70 (dd, 1H, $J=6.2, 11.3$ Hz, $H_{5'b}$), 3.79 (dd, 1H, $J=2.6, 12.0$ Hz, H_{3b}), 4.19 (ddd, 1H, $J=1.8, 4.9, 6.2$ Hz, $H_{4'}$), 4.49 (dd, 1H, $J=1.8, 5.3$ Hz, $H_{3'}$), 4.67 (d, 1H, $J=1.8$ Hz, $H_{1'}$), 4.68 (dd, 1H, $J=1.8, 5.3$ Hz, $H_{2'}$), 6.22 (dd, 1H, $J=4.2, 7.7$ Hz, H_5), 7.31–7.59 (m, 10H), 7.93 (d, 1H, $J=6.1$ Hz, H_6), 9.22 (d, 1H, $J=4.4$ Hz, NH). ^{13}C NMR (CDCl_3 , 125 MHz) δ : 19.2, 25.1, 26.81, 26.85, 29.7, 38.6, 62.1, 64.5, 64.6, 80.9, 82.8, 83.4, 86.2, 101.7, 113.5, 124.7 (d, $J=34.7$ Hz), 127.87, 127.95, 130.09, 130.11, 132.5, 132.7, 135.4, 135.5, 140.0 (d, $J=236.2$ Hz), 149.0, 156.8 (d, $J=26.9$ Hz). Anal. calcd for $\text{C}_{32}\text{H}_{40}\text{FN}_3\text{O}_8\text{Si}$: C, 59.89; H, 6.28; N, 6.55%. Found: C, 60.13; H, 6.26; N, 6.53%.

3.6. General procedure for hydrolysis of homochiral isoxazolidines 9b,c and 10b,c

Isoxazolidines **9b,c** and **10b,c** were dissolved in a 1.5% HCl solution in EtOH (ca. 2.5 mL), and the reaction mixture was stirred at room temperature for 3 h. The solution was brought to pH 10 by adding aqueous 10% sodium carbonate and extracted with dichloromethane (2 $\times$ 10 mL). The organic phase, dried over sodium sulfate, was filtered and evaporated to dryness. The residue was purified by radial chromatography (chloroform/methanol 9:1) to furnish homochiral *N,O*-nucleosides **11b,c** and **12b,c**.

3.6.1. 1-[(3R,5R)-3-(Hydroxymethyl)isoxazolidin-5-yl]-5-methylpyrimidine-2,4(1H,3H)-dione 11b. Yield 73%; HPLC: t_R 20.0 min. colourless oil; $[\alpha]_D^{25} = -102.4$ (c 0.12; H_2O). ^1H NMR (D_2O , 500 MHz) δ : 1.92 (d, 3H, $J=0.9$ Hz), 2.58 (ddd, 1H, $J=4.9, 7.9, 13.9$ Hz, H_{4a}), 2.71 (ddd, 1H, $J=3.6, 7.7, 13.9$ Hz, H_{4b}), 3.65 (d, 2H, $J=6.0$ Hz, $H_{3'}$), 3.85 (ddd, 1H, $J=4.9, 6.0, 7.7$ Hz,

$H_{3'}$), 6.13 (dd, 1H, $J=3.6, 7.9$ Hz, H_5), 7.55 (q, 1H, $J=0.9$ Hz, H_6). ^{13}C NMR (D_2O , 125 MHz) δ : 11.5, 36.5, 60.6, 61.5, 81.3, 111.0, 138.9, 151.9, 166.8. Anal. calcd for $\text{C}_9\text{H}_{13}\text{N}_3\text{O}_4$: C, 47.57; H, 5.76; N, 18.49%. Found: C, 47.42; H, 5.74; N, 18.56%.

3.6.2. 1-[(3R,5S)-3-(Hydroxymethyl)isoxazolidin-5-yl]-5-methylpyrimidine-2,4(1H,3H)-dione 12b. Yield 77%; HPLC: t_R 22.2 min. colourless oil; $[\alpha]_D^{25} = +108.3$ (c 0.06; H_2O). ^1H NMR (D_2O , 500 MHz) δ : 1.92 (d, 3H, $J=1.3$ Hz), 2.35 (ddd, 1H, $J=6.2, 8.2, 13.7$ Hz, H_{4a}), 2.87 (ddd, 1H, $J=7.7, 7.8, 13.7$ Hz, H_{4b}), 3.72 (dddd, 1H, $J=4.4, 6.1, 7.7, 8.2$ Hz, H_3), 3.78 (dd, 1H, $J=6.1, 11.9$ Hz, $H_{3'a}$), 3.84 (dd, 1H, $J=4.4, 11.9$ Hz, $H_{3'b}$), 6.12 (dd, 1H, $J=6.2, 7.8$ Hz, H_5), 7.63 (q, 1H, $J=1.3$ Hz, H_6). ^{13}C NMR (D_2O , 125 MHz) δ : 13.9, 38.3, 62.5, 63.9, 86.1, 113.5, 141.1, 150.7, 162.2. Anal. calcd for $\text{C}_9\text{H}_{13}\text{N}_3\text{O}_4$: C, 47.57; H, 5.76; N, 18.49%. Found: C, 47.44; H, 5.79; N, 18.44%.

3.6.3. 5-Fluoro-1-[(3R,5R)-3-(hydroxymethyl)isoxazolidin-5-yl]pyrimidine-2,4(1H,3H)-dione 11c. Yield 75%; colourless oil; $[\alpha]_D^{25} = -89.7$ (c 0.15; H_2O). ^1H NMR (D_2O , 500 MHz) δ : 2.61 (ddd, 1H, $J=5.3, 7.4, 14.3$ Hz, H_{4a}), 2.71 (ddd, 1H, $J=3.4, 7.6, 14.3$ Hz, H_{4b}), 3.66 (d, 2H, $J=5.9$ Hz, $H_{3'}$), 3.83 (ddt, 1H, $J=5.3, 5.9, 7.6$ Hz, H_3), 6.14 (dd, 1H, $J=3.4, 7.4$ Hz, H_5), 7.95 (d, 1H, $J=6.4$ Hz, H_6). ^{13}C NMR (D_2O , 125 MHz) δ : 39.2, 62.6, 63.6, 91.9, 129.34 (d, $J=34.0$ Hz), 142.9 (d, $J=231.9$ Hz), 152.7, 158.3 (d, $J=26.7$ Hz). Anal. calcd for $\text{C}_8\text{H}_{10}\text{FN}_3\text{O}_4$: C, 41.56; H, 4.36; N, 18.18%. Found: C, 41.51; H, 4.34; N, 18.19%.

3.6.4. 5-Fluoro-1-[(3R,5S)-3-(hydroxymethyl)isoxazolidin-5-yl]pyrimidine-2,4(1H,3H)-dione 12c. Yield 78%; white solid: mp 133–134°C from EtOH; $[\alpha]_D^{25} = +57.9$ (c 0.16; H_2O). ^1H NMR (D_2O , 500 MHz) δ : 2.33 (dd, 1H, $J=6.0, 14.1$ Hz, H_{4a}), 2.91 (ddd, 1H, $J=7.2, 7.5, 14.1$ Hz, H_{4b}), 3.66–3.83 (m, 3H, H_3 and $H_{3'}$), 6.11 (dd, 1H, $J=6.0, 7.2$ Hz, H_5), 8.02 (d, 1H, $J=6.4$ Hz, H_6). ^{13}C NMR (D_2O , 125 MHz) δ : 36.5, 61.3, 63.9, 89.8, 127.4 (d, $J=34.1$ Hz), 141.1 (d, $J=230.6$ Hz), 150.5, 158.6 (d, $J=27.1$ Hz). Anal. calcd for $\text{C}_8\text{H}_{10}\text{FN}_3\text{O}_4$: C, 41.56; H, 4.36; N, 18.18%. Found: C, 41.43; H, 4.35; N, 18.19%.

Acknowledgements

We thank MIUR and CNR for their financial support.

References

- De Clercq, E. *Biochim. Biophys. Acta* **2002**, *1587*, 258–275.
- (a) De Muys, J.-M.; Gordeau, H.; Nguyen-Ba, N.; Taylor, D. L.; Ahmed, P. S.; Mansour, T.; Locas, C.; Richard, N.; Wainberg, M. A.; Rando, R. F. *Antimicrob. Agents Chemother.* **1999**, *43*, 1835–1844; (b) Zhu, X. F. *Nucleos. Nucleot. Nucleic Acids* **2000**, *19*, 651–690; (c) Crimmins, M. T. *Tetrahedron* **1998**, *54*, 9229–9272.

3. (a) Pan, S.; Amankulor, N. M.; Zhao, K. *Tetrahedron* **1998**, *54*, 6587–6604; (b) Merino, P. *Curr. Med. Chem.* **2002**, *1*, 389–411; (c) Tronchet, J. M. J.; Iznaden, M.; Barlat-Rey, F.; Dhimané, H.; Ricca, A.; Balzarini, J.; De Clercq, E. *Eur. J. Med. Chem.* **1992**, *27*, 555–560; (d) Tronchet, J. M. J.; Iznaden, M.; Barbalat-Rey, F.; Komaromi, I.; Dolatshahi, N.; Bernardinelli, G. *Nucleosides Nucleotides* **1995**, *14*, 1737–1758.
4. (a) Fischer, R.; Drucková, A.; Fišera, L.; Rybár, A.; Hametner, C.; Cyranski, M. *Synlett* **2002**, 1113–1117; (b) Chiacchio, U.; Corsaro, A.; Iannazzo, D.; Piperno, A.; Rescifina, A.; Romeo, R.; Romeo, G. *Tetrahedron Lett.* **2001**, *42*, 1777–1780; (c) Chiacchio, U.; Corsaro, A.; Iannazzo, D.; Piperno, A.; Procopio, A.; Rescifina, A.; Romeo, G.; Romeo, R. *Eur. J. Org. Chem.* **2001**, 1893–1898; (d) Iannazzo, D.; Piperno, A.; Pistarà, V.; Rescifina, A.; Romeo, R. *Tetrahedron* **2002**, *58*, 581–587; (e) Chiacchio, U.; Corsaro, A.; Pistarà, V.; Rescifina, A.; Iannazzo, D.; Piperno, A.; Romeo, G.; Romeo, R.; Grassi, G. *Eur. J. Org. Chem.* **2002**, 1206–1212.
5. (a) Leggio, A.; Liguori, A.; Procopio, A.; Siciliano, C.; Sindona, G. *Tetrahedron Lett.* **1996**, *37*, 1277–1280; (b) Leggio, A.; Liguori, A.; Procopio, A.; Siciliano, C.; Sindona, G. *Nucleosides Nucleotides* **1997**, *16*, 1515–1518; (c) Colacino, E.; Converso, A.; Liguori, A.; Napoli, A.; Siciliano, C.; Sindona, G. *Tetrahedron* **2001**, *57*, 8551–8557; (d) Dalpozzo, R.; De Nino, A.; Maiuolo, L.; Procopio, A.; De Munno, G.; Sindona, G. *Tetrahedron* **2001**, *57*, 4035–4038.
6. Chiacchio, U.; Rescifina, A.; Corsaro, A.; Pistarà, V.; Romeo, G.; Romeo, R. *Tetrahedron: Asymmetry* **2000**, *11*, 2045–2048.
7. Chiacchio, U.; Corsaro, A.; Iannazzo, D.; Piperno, A.; Pistarà, V.; Rescifina, A.; Romeo, R.; Valveri, V.; Mastino, A.; Romeo, G. *J. Med. Chem.* **2003**, in press.
8. Challand, R.; Young, R. *Antiviral Chemotherapy*; Oxford University Press: Oxford, 1998.
9. (a) Vasella, A. *Helv. Chim. Acta* **1977**, *60*, 426–446; (b) Mzengeza, S.; Whitney, R. A. *J. Org. Chem.* **1988**, *53*, 4074–4081; (c) Kasahara, K.; Iida, H.; Kibasyashi, C. *J. Org. Chem.* **1989**, *54*, 2225–2233.
10. Chiacchio, U.; Corsaro, A.; Gumina, G.; Rescifina, A.; Iannazzo, D.; Piperno, A.; Romeo, G.; Romeo, R. *J. Org. Chem.* **1999**, *64*, 9321–9327.
11. Stewart, J. J. P. *J. Comput. Chem.* **1989**, *10*, 209–220, and 221–264.
12. Merino, P.; Revuelta, J.; Tejero, T.; Chiacchio, U.; Rescifina, A.; Romeo, G. *Tetrahedron* **2003**, *59*, 3581–3592.
13. For **13a,b**: Dalpozzo, R.; De Nino, A.; Maiuolo, L.; Procopio, A.; Romeo, R.; Sindona, A. *Synthesis* **2002**, 172–174; for **13c**: Gacek, M.; Undheim, K. *Acta Chem. Scandinavica, Series B*, **1979**, *B33*, 515–518.